136 related articles for article (PubMed ID: 34352659)
1. Reliability of a computational platform as a surrogate for manually interpreted immunohistochemical markers in breast tumor tissue microarrays.
Roberts MR; Baker GM; Heng YJ; Pyle ME; Astone K; Rosner BA; Collins LC; Eliassen AH; Tamimi RM
Cancer Epidemiol; 2021 Oct; 74():101999. PubMed ID: 34352659
[TBL] [Abstract][Full Text] [Related]
2. Reliability of CD44, CD24, and ALDH1A1 immunohistochemical staining: Pathologist assessment compared to quantitative image analysis.
Yaghjyan L; Heng YJ; Baker GM; Bret-Mounet V; Murthy D; Mahoney MB; Mu Y; Rosner B; Tamimi RM
Front Med (Lausanne); 2022; 9():1040061. PubMed ID: 36590957
[TBL] [Abstract][Full Text] [Related]
3. Assessment of automated image analysis of breast cancer tissue microarrays for epidemiologic studies.
Bolton KL; Garcia-Closas M; Pfeiffer RM; Duggan MA; Howat WJ; Hewitt SM; Yang XR; Cornelison R; Anzick SL; Meltzer P; Davis S; Lenz P; Figueroa JD; Pharoah PD; Sherman ME
Cancer Epidemiol Biomarkers Prev; 2010 Apr; 19(4):992-9. PubMed ID: 20332278
[TBL] [Abstract][Full Text] [Related]
4. Continuous measurement of breast tumour hormone receptor expression: a comparison of two computational pathology platforms.
Ahern TP; Beck AH; Rosner BA; Glass B; Frieling G; Collins LC; Tamimi RM
J Clin Pathol; 2017 May; 70(5):428-434. PubMed ID: 27729430
[TBL] [Abstract][Full Text] [Related]
5. Immunohistochemistry scoring of breast tumor tissue microarrays: A comparison study across three software applications.
Baker GM; Bret-Mounet VC; Wang T; Veta M; Zheng H; Collins LC; Eliassen AH; Tamimi RM; Heng YJ
J Pathol Inform; 2022; 13():100118. PubMed ID: 36268097
[TBL] [Abstract][Full Text] [Related]
6. Quantitative comparison and reproducibility of pathologist scoring and digital image analysis of estrogen receptor β2 immunohistochemistry in prostate cancer.
Rizzardi AE; Zhang X; Vogel RI; Kolb S; Geybels MS; Leung YK; Henriksen JC; Ho SM; Kwak J; Stanford JL; Schmechel SC
Diagn Pathol; 2016 Jul; 11(1):63. PubMed ID: 27401406
[TBL] [Abstract][Full Text] [Related]
7. Comparing computer-generated and pathologist-generated tumour segmentations for immunohistochemical scoring of breast tissue microarrays.
Akbar S; Jordan LB; Purdie CA; Thompson AM; McKenna SJ
Br J Cancer; 2015 Sep; 113(7):1075-80. PubMed ID: 26348443
[TBL] [Abstract][Full Text] [Related]
8. Membrane connectivity estimated by digital image analysis of HER2 immunohistochemistry is concordant with visual scoring and fluorescence in situ hybridization results: algorithm evaluation on breast cancer tissue microarrays.
Laurinaviciene A; Dasevicius D; Ostapenko V; Jarmalaite S; Lazutka J; Laurinavicius A
Diagn Pathol; 2011 Sep; 6():87. PubMed ID: 21943197
[TBL] [Abstract][Full Text] [Related]
9. Quantitative comparison of immunohistochemical staining measured by digital image analysis versus pathologist visual scoring.
Rizzardi AE; Johnson AT; Vogel RI; Pambuccian SE; Henriksen J; Skubitz AP; Metzger GJ; Schmechel SC
Diagn Pathol; 2012 Jun; 7():42. PubMed ID: 22515559
[TBL] [Abstract][Full Text] [Related]
10. Feasibility of using tissue microarrays for the assessment of HER-2 gene amplification by fluorescence in situ hybridization in breast carcinoma.
Bhargava R; Lal P; Chen B
Diagn Mol Pathol; 2004 Dec; 13(4):213-6. PubMed ID: 15538111
[TBL] [Abstract][Full Text] [Related]
11. Intratumoral heterogeneity as a source of discordance in breast cancer biomarker classification.
Allott EH; Geradts J; Sun X; Cohen SM; Zirpoli GR; Khoury T; Bshara W; Chen M; Sherman ME; Palmer JR; Ambrosone CB; Olshan AF; Troester MA
Breast Cancer Res; 2016 Jun; 18(1):68. PubMed ID: 27349894
[TBL] [Abstract][Full Text] [Related]
12. Impact of tissue sampling on accuracy of Ki67 immunohistochemistry evaluation in breast cancer.
Besusparis J; Plancoulaine B; Rasmusson A; Augulis R; Green AR; Ellis IO; Laurinaviciene A; Herlin P; Laurinavicius A
Diagn Pathol; 2016 Aug; 11(1):82. PubMed ID: 27576949
[TBL] [Abstract][Full Text] [Related]
13. Artificial Intelligence Algorithms to Assess Hormonal Status From Tissue Microarrays in Patients With Breast Cancer.
Shamai G; Binenbaum Y; Slossberg R; Duek I; Gil Z; Kimmel R
JAMA Netw Open; 2019 Jul; 2(7):e197700. PubMed ID: 31348505
[TBL] [Abstract][Full Text] [Related]
14. Comparison of central laboratory assessments of ER, PR, HER2, and Ki67 by IHC/FISH and the corresponding mRNAs (ESR1, PGR, ERBB2, and MKi67) by RT-qPCR on an automated, broadly deployed diagnostic platform.
Wu NC; Wong W; Ho KE; Chu VC; Rizo A; Davenport S; Kelly D; Makar R; Jassem J; Duchnowska R; Biernat W; Radecka B; Fujita T; Klein JL; Stonecypher M; Ohta S; Juhl H; Weidler JM; Bates M; Press MF
Breast Cancer Res Treat; 2018 Nov; 172(2):327-338. PubMed ID: 30120700
[TBL] [Abstract][Full Text] [Related]
15. Comprehensive evaluation of methods to assess overall and cell-specific immune infiltrates in breast cancer.
Nederlof I; De Bortoli D; Bareche Y; Nguyen B; de Maaker M; Hooijer GKJ; Buisseret L; Kok M; Smid M; Van den Eynden GGGM; Brinkman AB; Hudecek J; Koster J; Sotiriou C; Larsimont D; Martens JWM; van de Vijver MJ; Horlings HM; Salgado R; Biganzoli E; Desmedt C
Breast Cancer Res; 2019 Dec; 21(1):151. PubMed ID: 31878981
[TBL] [Abstract][Full Text] [Related]
16. Digital imaging in the immunohistochemical evaluation of the proliferation markers Ki67, MCM2 and Geminin, in early breast cancer, and their putative prognostic value.
Joshi S; Watkins J; Gazinska P; Brown JP; Gillett CE; Grigoriadis A; Pinder SE
BMC Cancer; 2015 Jul; 15():546. PubMed ID: 26205655
[TBL] [Abstract][Full Text] [Related]
17. Association of body mass index and inflammatory dietary pattern with breast cancer pathologic and genomic immunophenotype in the nurses' health study.
Asad S; Damicis A; Heng YJ; Kananen K; Collier KA; Adams EJ; Kensler KH; Baker GM; Wesolowski R; Sardesai S; Gatti-Mays M; Ramaswamy B; Eliassen AH; Hankinson SE; Tabung FK; Tamimi RM; Stover DG
Breast Cancer Res; 2022 Nov; 24(1):78. PubMed ID: 36376974
[TBL] [Abstract][Full Text] [Related]
18. Comparison of immunohistochemistry and RT-qPCR for assessing ER, PR, HER2, and Ki67 and evaluating subtypes in patients with breast cancer.
Chen L; Chen Y; Xie Z; Luo J; Wang Y; Zhou J; Huang L; Li H; Wang L; Liu P; Shu M; Zhang W; Ke Z
Breast Cancer Res Treat; 2022 Aug; 194(3):517-529. PubMed ID: 35789315
[TBL] [Abstract][Full Text] [Related]
19. Digital image analysis of Ki67 proliferation index in breast cancer using virtual dual staining on whole tissue sections: clinical validation and inter-platform agreement.
Koopman T; Buikema HJ; Hollema H; de Bock GH; van der Vegt B
Breast Cancer Res Treat; 2018 May; 169(1):33-42. PubMed ID: 29349710
[TBL] [Abstract][Full Text] [Related]
20. Validity and Reproducibility of Immunohistochemical Scoring by Trained Non-Pathologists on Tissue Microarrays.
Jenniskens JCA; Offermans K; Samarska I; Fazzi GE; Simons CCJM; Smits KM; Schouten LJ; Weijenberg MP; van den Brandt PA; Grabsch HI
Cancer Epidemiol Biomarkers Prev; 2021 Oct; 30(10):1867-1874. PubMed ID: 34272264
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
